Recent clinical data has demonstrated that low dose IL-2 infusions can substantially augment pTreg frequency and reduce disease severity in in chronic graft-versus-host disease (cGVHD) patients (Zorn et al., 2005; Matsuoka et al., 2013; Koreth et al., 2016). The gene discussed is IL2; the disease is chronic graft versus host disease.